Site Search
332 Results (showing 1 - 25)
Dec 30, 2004
Japanese Researchers Sequence Genome of Thermophile Bacterium G. kaustophilus
NEWSBRIEF
Dec 30, 2004
FDA Publishes PGx Guidance in Federal Register; Final Document Now Due Early 2005
NEWSBRIEF
Dec 30, 2004
NIH, International Consortium, Set Aside $21M in RFA for Research Into Genetics in Autism
NEWSBRIEF
Dec 30, 2004
NOTE TO GENOMEWEB NEWS SUBSCRIBERS: Dec 30, 2004
In observance of the New Year, GenomeWeb News will not publish on Friday, Dec. 31. We will resume reporting for our twice-daily news bulletins on Monday, Jan. 3.
Dec 28, 2004
Biolog Recently Wins $2M in NIH Grants; Firm to Further Develop Phenotype Microrrary
NEWSBRIEF
Dec 27, 2004
Tripos to Buy Optive for $8M
Tripos last week said that it plans to acquire privately held discovery informatics firm Optive Research in a cash-and-stock transaction worth $8 million.
Dec 27, 2004
Less than two months after its purchase of Silicon Genetics, Agilent Technologies is hard at work identifying new application areas for the GeneSpring software platform, with the area of comparative genomic hybridization analysis on the short-term horizon, according to a company executive...Subscribers: click headline for more
Dec 27, 2004
Cold Spring Harbor Lab to Pocket $1M From US Gov t to Help Build Center for Women s Genomics
NEWSBRIEF
Dec 27, 2004
Definiens has released version 3.0 of its Proteomweaver 2D gel analysis software.
Dec 27, 2004
Researchers at Lawrence Berkeley National Laboratory have contributed another choice to a growing number of pathway analysis software tools with the launch of GenoPharm, a search engine that maps functional relationship networks among genes, drugs, and diseases...Subscribers: click headline for more
Dec 27, 2004
Sren Brunak, John Sulston, Anna Tramontano, Martin Vingron, Gunnar von Heijne, Christopher Yoo
Premium
EMBL has established a Bioinformatics Advisory Committee.
Dec 27, 2004
It appears that the commercial bioinformatics sector has passed through the darkest days of a precipitous downturn that it entered over two years ago, witnessing far fewer consolidation events during 2004 than it saw in previous years -- accompanied by several more pharma deals and VC funding rounds...Subscribers: click headline for more